SBC Medical Group Holdings Incorporated (SBC) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (73% profit margin, 63% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SBC Medical Group Holdings Incorporated (SBC) surged +4.40% to $5.69, trading at 97% of its 52-week range ($2.78 – $5.79). High-quality cash engine (73% profit margin, 63% return on capital) with steady institutional support.
2026-10-27. The following slide deck was published by SBC Medical Group Holdings Incorporated in conjunction with this event.
IRVINE, Calif., October 22, 2026--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("The Company" or "SBC Medical"), a Medical Services Organization (MSO) providing management support across a wide range of healthca
SBC Medical Group Holdings Incorporated (NASDAQ:SBC) ("The Company" or "SBC Medical"), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -15.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SBC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SBC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, SBC Medical Group Holdings Incorporated (SBC) ranks #87 by composite RQD confidence (71/100, grade B-) and #425 by equity capitalization ($585.2M). Within this direct 5-issuer industry benchmark cohort, SRTA leads on earnings valuation at 10.2x trailing P/E, while SBC leads on capital efficiency and profitability with 63.1% ROIC and 73.3% gross margin. SBC currently leads its immediate peer cohort in composite quantitative strength at 71/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SBC
ACTIVE
SBC Medical Group Holdings Incorporated | B- | 71/100 | 11.5x | 73.3% | 63.1% | +4.40% | $585.2M | Benchmark Subject |
| STLN Starling Oncology Inc. | D- | 37/100 | — | — | -35.0% | +0.15% | $677.7M | /stln-vs-sbc → |
| AHCO AdaptHealth Corp. | D | 45/100 | — | 18.8% | 2.2% | -1.66% | $808.5M | /ahco-vs-sbc → |
| SRTA Strata Critical Medical Inc. (Class A) | D | 47/100 | 10.2x | 20.9% | -7.1% | -0.21% | $420.2M | /srta-vs-sbc → |
| AUNA Auna SA (Class A) | C- | 61/100 | — | — | — | +1.27% | $355.3M | /auna-vs-sbc → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), SBC Medical Group Holdings Incorporated (SBC) reported GAAP revenue of $173.6M (-15.5% vs. FY2024 revenue of $205.4M , and -10.3% cumulative change since FY2023) , GAAP net income of $51.0M, operating cash flow of $24.7M, and free cash flow of $23.3M (+29.1% YoY). On the balance sheet, SBC closed FY2025 with $380.4M in total assets against $0 in total debt (Altman Z-Score: 5.46, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $173.6M | $51.0M | $24.7M | $23.3M | $380.4M | — |
| FY2024 (FY) | 2024-12-31 | $205.4M | $46.6M | $20.6M | $18.0M | $266.1M | — |
| FY2023 (FY) | 2023-12-31 | $193.5M | $39.4M | $50.7M | $50.7M | — | — |
As of 2026-11-01, SBC Medical Group Holdings Incorporated (NASDAQ: SBC) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $5.69 (+4.40% 1D, market cap $585.2M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, SBC ranks #87 in composite RQD confidence.
Within the Health Care sector (Medical/Nursing Services), SBC carries a Roarable B- (71/100 RQD), trailing P/E of 11.5x, gross margin of 73.3%, and ROIC of 63.1%. By comparison, STLN (Starling Oncology Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $677.7M) and AHCO (AdaptHealth Corp.) posts a D grade (45/100 RQD, P/E N/A, ROIC 2.2%, cap $808.5M). Among the 5-stock peer group, SRTA leads on earnings multiple (10.2x) while SBC leads on capital efficiency (63.1% ROIC).
Per SBC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001930313), SBC Medical Group Holdings Incorporated generated $173.6M in revenue (-15.5% YoY), $51.0M in net income, and $23.3M in free cash flow against $380.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (73% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
SBC last traded at $5.69 (+4.40% on volume of 258,973 shares), positioning the stock +16.84% above its 50-day simple moving average ($4.87) and +45.52% above its 200-day simple moving average ($3.91). Across its 52-week range of $2.78 to $5.79, SBC sits at the 96.7% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of ±10.6% ($5.09 to $6.29).
Why SBC Stock surged +4.40% Today — RQD Quant Desk Flash. High-quality cash engine (73% profit margin, 63% return on capital) with steady institutional support.